Ondine Biomedical (FRA:VF5) ROCE %: -656.02% (As of Dec. 2024)


FRA:VF5 Ondine Biomedical Inc FRA:VF5
47 GF Score
Price €0.15
View Full Analysis

What is Ondine Biomedical ROCE %?

Ondine Biomedical FRA:VF5 47 ROCE % is -656.02% as of Dec. 2024. GuruFocus rates FRA:VF5 with a GF Score™ of 47/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ondine Biomedical's annualized ROCE % for the quarter that ended in Dec. 2024 was -656.02%.

Ondine Biomedical  (FRA:VF5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ondine Biomedical ROCE % Related Terms

Ondine Biomedical ROCE % Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical ROCE % Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -90.53 -190.17 -415.69

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.02 -180.93 -367.09 -1,356.69 -656.02
FRA:VF5
47GF Score
Ondine Biomedical Inc FRA:VF5
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical ROCE % Calculation

Ondine Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-12.77/( ( (3.919 - 2.385) + (8.595 - 3.985) )/ 2 )
=-12.77/( (1.534+4.61)/ 2 )
=-12.77/3.072
=-415.69 %

Ondine Biomedical's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-15.164/( ( (2.728 - 2.715) + (8.595 - 3.985) )/ 2 )
=-15.164/( ( 0.013 + 4.61 )/ 2 )
=-15.164/2.3115
=-656.02 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -656.02% mean?
Ondine Biomedical (FRA:VF5) has a ROCE % of -656.02% as of Dec. 2024.
Is Ondine Biomedical's ROCE % too high?
Ondine Biomedical's current ROCE % is -656.02%. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's ROCE % compare to VRTX and REGN?
Ondine Biomedical's ROCE % of -656.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Ondine Biomedical's current ROCE % is -656.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current ROCE % of -656.02%. The current ROCE % is -656.02%. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current ROCE % is -656.02% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ondine Biomedical Business Description

Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score

Get the complete analysis for FRA:VF5

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price